(Q38006567)

English

RNA-based vaccines

scientific article published on 28 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

RNA-based vaccines (English)

1 reference

Europe PubMed Central

26 August 2017

0 references

author name string

Jeffrey B Ulmer

1

1 reference

Europe PubMed Central

26 August 2017

Peter W Mason

2

1 reference

Europe PubMed Central

26 August 2017

Andrew Geall

3

1 reference

Europe PubMed Central

26 August 2017

Christian W Mandl

4

1 reference

Europe PubMed Central

26 August 2017

language of work or name

0 references

publication date

28 April 2012

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

30

1 reference

Europe PubMed Central

26 August 2017

30

1 reference

Europe PubMed Central

26 August 2017

4414-4418

1 reference

Europe PubMed Central

26 August 2017

Vaccines for the twenty-first century society.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Clinical applications of DNA vaccines: current progress

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Plasmid DNA production for therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Electroporation delivery of DNA vaccines: prospects for success

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Cytokine-adjuvanted HIV-DNA vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Viral vectors as vaccine platforms: deployment in sight

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Messenger RNA-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Self-replicating Semliki Forest virus RNA as recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Cancer therapy using a self-replicating RNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

mRNA vaccination as a safe approach for specific protection from type I allergy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Tumor vaccination using messenger RNA: prospects of a future therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Differential expression and stability of foreign genes introduced into human fibroblasts by nuclear versus cytoplasmic microinjection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Cellular and molecular barriers to gene transfer by a cationic lipid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Characterization of the ribonuclease activity on the skin surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

mRNA is an endogenous ligand for Toll-like receptor 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Vaccination with messenger RNA (mRNA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Current prospects for mRNA gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Long-term storage of DNA-free RNA for use in vaccine studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Gene expression in the muscle and central nervous system following intramuscular inoculation of encapsidated or naked poliovirus replicons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Mimicking live flavivirus immunization with a noninfectious RNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Intradermal electroporation of naked replicon RNA elicits strong immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.060

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.04.060

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38006567&oldid=2095149756"